RESMED INC
RMDHealthcareresmed.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 30, 2026
Next reportJanuary 27, 2027forecast 3.017 $/share
Revenue
$1.41B
▲ +5.9% vs prior year YoY
Net income
$418.41M
▲ +20.0% vs prior year YoY
EPS
2.92$
▲ +23.2% vs prior year YoY
Net margin
29.6%
▲ +3.5 pp vs prior year YoY
Revenue▲ +5.9%
Margins (% of revenue)GrossOperatingNet
Net income▲ +20.0%
EPS▲ +23.2%
Financial statements
View 10-Q filed October 30, 2026 on SEC ↗| Metric | Dec 2024 | Mar 2025 | Jun 2025* | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026* | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $1.28B | $1.29B | $1.35B | $1.34B | $1.42B | $1.43B | $1.46B | $1.41B | ▲ +5.9% |
| Gross profit | $751.27M | $766.41M | $820.07M | $817.66M | $878.72M | $890.98M | $861.22M | $870.57M | ▲ +6.5% |
| Operating income | $417.24M | $426.27M | $454.54M | $446.54M | $491.66M | $499.81M | $448.71M | $452.98M | ▲ +1.4% |
| Net income | $344.62M | $365.04M | $379.70M | $348.54M | $392.59M | $398.73M | $383.43M | $418.41M | ▲ +20.0% |
| R&D | $81.37M | $83.94M | $86.44M | $89.48M | $90.97M | $94.27M | $105.73M | $102.86M | ▲ +15.0% |
| EPS (diluted) | 2.34 $ | 2.48 $ | — | 2.37 $ | 2.68 $ | 2.74 $ | — | 2.92 $ | ▲ +23.2% |
| Margins (% of revenue) | |||||||||
| Gross | 58.6 % | 59.3 % | 60.8 % | 61.2 % | 61.8 % | 62.2 % | 58.8 % | 61.5 % | ▲ +0.3 pt |
| Operating | 32.5 % | 33.0 % | 33.7 % | 33.4 % | 34.6 % | 34.9 % | 30.7 % | 32.0 % | ▼ -1.4 pt |
| Net | 26.9 % | 28.3 % | 28.2 % | 26.1 % | 27.6 % | 27.9 % | 26.2 % | 29.6 % | ▲ +3.5 pt |
| Balance sheet | |||||||||
| Assets | $7.14B | $7.57B | $8.17B | $8.31B | $8.50B | $8.78B | $8.97B | $8.21B | ▼ -1.2% |
| Liabilities | $1.89B | $2.02B | $2.21B | $2.19B | $2.18B | $2.29B | $2.38B | $2.26B | ▲ +3.5% |
| Equity | $5.25B | $5.55B | $5.97B | $6.12B | $6.32B | $6.49B | $6.59B | $5.95B | ▼ -2.8% |
| Cash | $521.94M | $932.71M | $1.21B | $1.38B | $1.42B | $1.66B | $1.47B | $1.01B | ▼ -27.0% |
| Capital | |||||||||
| Shares outstanding | 146.87M | 146.63M | 146.41M | 145.97M | 145.68M | 145.06M | 144.25M | 140.66M | ▼ -3.6% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.